Micro-cap Most Volatile Stocks: Amicus Therapeutics (NASDAQ:FOLD), Synthetic Biologics Inc (NYSEMKT:SYN), IsoRay (NYSEMKT:ISR), Ultra Clean (NASDAQ:UCTT)

According to a report by Reuters on Wednesday, New Jersey-based Amicus Therapeutics Inc. (NASDAQ:FOLD) announced that in a 24-month trial, its new drug migalastat was effective at reducing abnormal fat accumulation in kidney cells compared with placebo. The drug is being considered alone and in combination therapy for treating Fabry disease, a congenital disorder that can be debilitating and even fatal. Amicus Therapeutics, Inc. (NASDAQ:FOLD) … Continue reading Micro-cap Most Volatile Stocks: Amicus Therapeutics (NASDAQ:FOLD), Synthetic Biologics Inc (NYSEMKT:SYN), IsoRay (NYSEMKT:ISR), Ultra Clean (NASDAQ:UCTT)

Micro-cap Gainers: Synthetic Biologics Inc (NYSEMKT:SYN), GTT Communications (NYSEMKT:GTT), Golden Enterprises (NASDAQ:GLDC), NanoViricides (NYSEMKT:NNVC)

The board of directors of Synthetic Biologics, Inc (NYSEMKT:SYN) determined to hold its 2014 Annual Meeting of Stockholders (the “Annual Meeting”) on June 10, 2014. The record date, time and location of the Annual Meeting will be as set forth in the Company’s proxy statement for the Annual Meeting. Synthetic Biologics Inc (NYSEMKT:SYN) stock performance was 5.98% in last session and finished the day at … Continue reading Micro-cap Gainers: Synthetic Biologics Inc (NYSEMKT:SYN), GTT Communications (NYSEMKT:GTT), Golden Enterprises (NASDAQ:GLDC), NanoViricides (NYSEMKT:NNVC)

It was the biggest loser on the Bloomberg Massachusetts Index: Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY), down more than 12 percent. The Cambridge company is developing a new class of medicines based on RNA interference, or RNAi. Alnylam believes that RNAi therapeutics are a promising approach to silence disease-causing genes, according to its website. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stock performance was -12.11% in last session and finished … Continue reading Hot BiotecH Stocks: Alnylam Pharmaceuticals (NASDAQ:ALNY), Sangamo Biosciences (NASDAQ:SGMO), Dyax Corp. (NASDAQ:DYAX), Synthetic Biologics Inc (NYSEMKT:SYN)

Looking back to 160 days ago, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) priced a 14,300,000 share secondary stock offering at $3.50 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment would go up over the course of time and based on early trading on Wednesday. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) stock performance was -3.75% in last session and finished the … Continue reading Volatile Stocks at Biotech: ZIOPHARM Oncology (NASDAQ:ZIOP), Idenix Pharmaceuticals (NASDAQ:IDIX), Synthetic Biologics (NYSEMKT:SYN), Ariad Pharmaceuticals (NASDAQ:ARIA)

A colon cancer screening test under development at Madison-based Exact Sciences Corp. (NASDAQ:EXAS) can detect early-stage cancer better than other noninvasive approaches, according to a study published online Wednesday. EXACT Sciences Corporation (NASDAQ:EXAS) stock performance was 0.21% in last session and finished the day at $14.45. Traded volume was 7.74 million shares in the last session and the average volume of the stock remained 997,245.00 … Continue reading Biotech New Highs: EXACT Sciences Corporation (NASDAQ:EXAS), Synthetic Biologics (NYSEMKT:SYN), Amgen (NASDAQ:AMGN), Prothena Corporation (NASDAQ:PRTA)

Inovio Pharmaceuticals Inc (NYSEMKT:INO)’s shares climbed 4.96% to $3.60. The company on Mar. 17 reported financial results for the fourth quarter and year ended Dec. 31, 2013. Total revenue was $1.7 million and $13.5 million for the quarter and year ended December 31, 2013, as compared to $1.1 million and $4.1 million for the same periods in 2012. Inovio Pharmaceuticals Inc (NYSEMKT:INO) stock performance was … Continue reading Biotech Gainers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Galena Biopharma (NASDAQ:GALE), CEL-SCI Corporation (NYSEMKT:CVM), Synthetic Biologics (NYSEMKT:SYN)